Clinical Trial Update: A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1) [Phase 1, Phase 2]

View source ↗

Summary

Nuvalent's neladalkib (NVL-655) is being studied in a Phase 1/2 trial (ALKOVE-1) for patients with advanced non-small cell lung cancer and other ALK-driven soli…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Neladalkib (neladalkib)

Snippet

Sponsor: Nuvalent Inc. | Conditions: Locally Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1, Phase 2 | Status: RECRUITING